Gilead Sciences, Inc. (GILD): Price and Financial Metrics

Gilead Sciences, Inc. (GILD)

Today's Latest Price: $68.81 USD

0.19 (-0.28%)

Updated Aug 6 6:55pm

Add GILD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 343 in Biotech

See all "A" rated Strong Buy stocks

GILD Stock Summary

  • GILD has a higher market value than 97.97% of US stocks; more precisely, its current market capitalization is $88,909,986,592.
  • Gilead Sciences Inc's stock had its IPO on January 22, 1992, making it an older stock than 82.19% of US equities in our set.
  • The volatility of Gilead Sciences Inc's share price is greater than that of only 3.39% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Gilead Sciences Inc are INFI, AKBA, TNAV, MEET, and NOVN.
  • Visit GILD's SEC page to see the company's official filings. To visit the company's web site, go to
GILD Daily Price Range
GILD 52-Week Price Range

GILD Stock Price Chart Technical Analysis Charts

GILD Price/Volume Stats

Current price $68.81 52-week high $85.97
Prev. close $69.00 52-week low $60.89
Day low $68.62 Volume 8,318,000
Day high $69.63 Avg. volume 16,638,705
50-day MA $75.02 Dividend yield 3.95%
200-day MA $71.33 Market Cap 86.31B

Gilead Sciences, Inc. (GILD) Company Bio

Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

GILD Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$68.81$54.62 -21%

We started the process of determining a valid price forecast for Gilead Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Gilead Sciences Inc ranked in the 43th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Gilead Sciences Inc, consider:

  • The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.03%; that's greater than just 24% of US stocks we're applying DCF forecasting to.
  • Gilead Sciences Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 20.11% of tickers in our DCF set.
  • As a business, Gilead Sciences Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as GILD, try ICLR, DGX, EBS, FONR, and NVS.

GILD Latest News Stream

Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream

Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.

Gilead Sciences' (GILD) CEO Daniel O'Day on Q2 2020 Results - Earnings Call Transcript

Gilead Sciences, Inc. (GILD) Q2 2020 Earnings Conference Call July 30, 2020 4:00 PM ET Company Participants Douglas Maffei – Senior Director-Investor Relations Daniel O'Day – Chairman and Chief Executive Officer Johanna Mercier – Chief Commercial Officer Christi Shaw – Chief Executive Officer-Kite Andrew Dickinson – Chief Financial Officer Merdad...

SA Transcripts on Seeking Alpha | July 31, 2020

Gilead Sciences Inc. (GILD) Q2 2020 Earnings Call Transcript

Gilead Sciences Inc (NASDAQ: GILD) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: Douglas Maffei — Senior Director, Investor Relations Daniel O’Day — Chairman and Chief Executive Officer Johanna Mercier — Chief Commercial Officer Merdad Parsey — Chief Medical Officer Andrew Dickinson — Chief Financial Officer Diana Brainard — Senior Vice President, HIV and Emerging Viral Infections Analysts: Tyler Van Buren — Piper Sandler — Analyst Geoffrey […]

News Alphastreet | July 31, 2020

Gilead Sciences Inc. (GILD) Q2 2020 Earnings Call Transcript | AlphaStreet

Final earnings conference call transcript of Gilead Sciences Inc. - GILD stock

News Alphastreet | July 31, 2020

Gilead: Upside From Remdesivir May Be Priced In

Source: Barron's Gilead (GILD) reports quarterly earnings after-hours. Analysts expect revenue of $5.31 billion and EPS of $1.45. The revenue estimate implies a 4% decline Q/Q. Investors should focus on the following key items. Growth Continues To Stagnate I assumed growth was totally dead after sales from the company's HCV...

Shock Exchange on Seeking Alpha | July 30, 2020

Gilead Sciences sales fall 10% as drug demand falls due to coronavirus pandemic

Gilead Sciences' sales fell 10% in the second quarter from a year earlier as demand fell for some of its drugs because of the coronavirus pandemic.

CNBC | July 30, 2020

Read More 'GILD' Stories Here

GILD Price Returns

1-mo -8.99%
3-mo -10.41%
6-mo 1.74%
1-year 10.13%
3-year 3.80%
5-year -30.36%
YTD 7.83%
2019 7.88%
2018 -9.92%
2017 2.96%
2016 -27.59%
2015 8.63%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8824 seconds.